Skip to content

Study · Other design · 2021

8 results

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.

Pratley RE, Catarig AM, Lingvay I, Viljoen A, Paine A, Lawson J, Chubb B, Gorst-Rasmussen A, Miresashvili N

Diabetes, obesity & metabolism9 Aug 2021Cited by 20 (Europe PMC)

PMID34286894 (opens in a new tab)PMCIDPMC9291551 (opens in a new tab)DOI10.1111/dom.14497 (opens in a new tab)PepBankPUB-34286894
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanOther designEfficacy outcome

    In patients with type 2 diabetes, semaglutide 1.0 mg reduced HbA1c more than dulaglutide 3.0 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, semaglutide 1.0 mg reduced HbA1c more than dulaglutide 3.0 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c treatment difference
    Study

    n: not reported in source

    Comparator
    Dulaglutide 3.0 mg
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.24 percentage points
    semaglutide versus dulaglutide 3.0 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points (95% confidence interval [CI] -0.43, -0.05), with comparable reductions in HbA1c versus dulaglutide 4.5 mg with an ETD of -0.07%-points (95% CI -0.26, 0.12).
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  2. 02HumanOther designEfficacy outcome

    In patients with type 2 diabetes, dulaglutide 3.0 mg reduced HbA1c less than semaglutide 1.0 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, dulaglutide 3.0 mg reduced HbA1c less than semaglutide 1.0 mg in an indirect comparison.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c treatment difference
    Study

    n: not reported in source

    Comparator
    Semaglutide 1.0 mg
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.24 percentage points
    semaglutide 1.0 mg versus dulaglutide 3.0 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points (95% confidence interval [CI] -0.43, -0.05), with comparable reductions in HbA1c versus dulaglutide 4.5 mg with an ETD of -0.07%-points (95% CI -0.26, 0.12).
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  3. 03HumanOther designEfficacy outcome

    In patients with type 2 diabetes, HbA1c reductions were comparable for semaglutide 1.0 mg and dulaglutide 4.5 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, HbA1c reductions were comparable for semaglutide 1.0 mg and dulaglutide 4.5 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c treatment difference
    Study

    n: not reported in source

    Comparator
    Dulaglutide 4.5 mg
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.07 percentage points
    semaglutide versus dulaglutide 4.5 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points (95% confidence interval [CI] -0.43, -0.05), with comparable reductions in HbA1c versus dulaglutide 4.5 mg with an ETD of -0.07%-points (95% CI -0.26, 0.12).
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  4. 04HumanOther designEfficacy outcome

    In patients with type 2 diabetes, HbA1c reductions were comparable for dulaglutide 4.5 mg and semaglutide 1.0 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, HbA1c reductions were comparable for dulaglutide 4.5 mg and semaglutide 1.0 mg in an indirect comparison.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c treatment difference
    Study

    n: not reported in source

    Comparator
    Semaglutide 1.0 mg
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4.5 mgAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.07 percentage points
    semaglutide 1.0 mg versus dulaglutide 4.5 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points (95% confidence interval [CI] -0.43, -0.05), with comparable reductions in HbA1c versus dulaglutide 4.5 mg with an ETD of -0.07%-points (95% CI -0.26, 0.12).
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  5. 05HumanOther designEfficacy outcome

    In patients with type 2 diabetes, semaglutide 1.0 mg reduced weight more than dulaglutide 3.0 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, semaglutide 1.0 mg reduced weight more than dulaglutide 3.0 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight treatment difference
    Study

    n: not reported in source

    Comparator
    Dulaglutide 3.0 mg
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    Weight treatment difference
    −2.65 kg
    semaglutide versus dulaglutide 3.0 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced body weight versus dulaglutide 3.0 and 4.5 mg with an ETD of -2.65 kg (95% CI -3.57, -1.73) and -1.95 kg (95% CI -2.87, -1.03), respectively.
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  6. 06HumanOther designEfficacy outcome

    In patients with type 2 diabetes, dulaglutide 3.0 mg reduced weight less than semaglutide 1.0 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, dulaglutide 3.0 mg reduced weight less than semaglutide 1.0 mg in an indirect comparison.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBody weight treatment difference
    Study

    n: not reported in source

    Comparator
    Semaglutide 1.0 mg
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight treatment difference
    −2.65 kg
    semaglutide 1.0 mg versus dulaglutide 3.0 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced body weight versus dulaglutide 3.0 and 4.5 mg with an ETD of -2.65 kg (95% CI -3.57, -1.73) and -1.95 kg (95% CI -2.87, -1.03), respectively.
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  7. 07HumanOther designEfficacy outcome

    In patients with type 2 diabetes, semaglutide 1.0 mg reduced weight more than dulaglutide 4.5 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, semaglutide 1.0 mg reduced weight more than dulaglutide 4.5 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight treatment difference
    Study

    n: not reported in source

    Comparator
    Dulaglutide 4.5 mg
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    Weight treatment difference
    −1.95 kg
    semaglutide versus dulaglutide 4.5 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced body weight versus dulaglutide 3.0 and 4.5 mg with an ETD of -2.65 kg (95% CI -3.57, -1.73) and -1.95 kg (95% CI -2.87, -1.03), respectively.
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…
  8. 08HumanOther designEfficacy outcome

    In patients with type 2 diabetes, dulaglutide 4.5 mg reduced weight less than semaglutide 1.0 mg in an indirect comparison.

    In plain wordsIn patients with diabetes, dulaglutide 4.5 mg reduced weight less than semaglutide 1.0 mg in an indirect comparison.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBody weight treatment difference
    Study

    n: not reported in source

    Comparator
    Semaglutide 1.0 mg
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4.5 mgAs given in this study (human).

    Measurements

    Weight treatment difference
    −1.95 kg
    semaglutide 1.0 mg versus dulaglutide 4.5 mg

    Source sentences

    Summary
    Semaglutide 1.0 mg significantly reduced body weight versus dulaglutide 3.0 and 4.5 mg with an ETD of -2.65 kg (95% CI -3.57, -1.73) and -1.95 kg (95% CI -2.87, -1.03), respectively.
    1 context sentence
    Summary · context
    To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes.Materials and methodsA Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg using…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06243536

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

University Hospital Sestre Milosrdnicen = 60est. 1 Feb 2024 to est. 31 Dec 2024

Type 2 Diabetes · Overweight · Disordered Eating Behaviors

Trial pageClinicalTrials.govUpdated 6 Feb 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.